Skip to main content
JINLING PHARMACEUTICAL CO.,LTD logo

JINLING PHARMACEUTICAL CO.,LTD — Investor Relations & Filings

Ticker · 000919 ISIN · CNE0000010W5 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,771 across all filing types
Latest filing 2017-12-22 Declaration of Voting R…
Country CN China
Listing Shenzhen Stock Exchange 000919

About JINLING PHARMACEUTICAL CO.,LTD

https://www.jlyy1999.com

Jinling Pharmaceutical Co., Ltd. specializes in the research, development, manufacture, and sale of pharmaceutical products, with a focus on chemical drugs and traditional Chinese medicine preparations. The company’s product portfolio primarily targets cardiovascular and cerebrovascular diseases, anti-tumor treatments, and digestive system health. A prominent product in its lineup is the Mailuoning Injection, utilized for treating various vascular conditions. In addition to its manufacturing operations, the company is involved in the management and operation of medical institutions, integrating clinical services with pharmaceutical production. Its business model emphasizes the synergy between drug development and healthcare service delivery to provide integrated medical solutions.

Recent filings

Filing Released Lang Actions
2017年第一次临时股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a formal announcement of the resolutions passed at the 2017 first extraordinary general meeting (临时股东大会) of Jinling Pharmaceutical Co., Ltd. It details the meeting date, voting procedures, attendance, voting results, and legal opinions confirming the validity of the meeting and resolutions. There is no financial data or detailed report content, only the official voting results and procedural information. The document length is about 2058 characters, which is relatively short and consistent with an announcement rather than a full report. This matches the definition of a Declaration of Voting Results & Voting Rights Announcements (DVA).
2017-12-22 Chinese
关于召开2017年第一次临时股东大会的提示性公告
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a detailed announcement regarding the convening of the 2017 first extraordinary general meeting (临时股东大会) of Jinling Pharmaceutical Co., Ltd. It includes information about the meeting date, voting procedures (both onsite and online), agenda items (notably a proposal to amend the company articles of association), registration methods, and proxy voting instructions. The document does not contain financial statements or results but serves as a notice and procedural guide for shareholders to participate in the meeting and vote on proposals. It is not a report of the meeting results, nor is it a proxy solicitation or voting results announcement. Given the detailed nature of the meeting notice and instructions, this fits the category of a shareholder meeting announcement rather than a report or results declaration. According to the filing definitions, this corresponds to a Proxy Solicitation & Information Statement (PSI), which includes materials sent to shareholders to provide information and request votes for meetings. The document length is under 5,000 characters, but it is substantive and not merely a brief announcement or report publication notice. Therefore, the best classification is PSI.
2017-12-18 Chinese
关于召开2017年第一次临时股东大会的通知
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a notice about convening the 2017 first extraordinary general meeting of shareholders for Jinling Pharmaceutical Co., Ltd. It details the meeting date, voting procedures, agenda items, and proxy authorization forms. It does not contain financial statements or results but is an announcement related to a shareholders meeting. The content fits the category of a Proxy Solicitation & Information Statement (PSI), as it provides information to shareholders to solicit votes for the meeting proposals.
2017-12-05 Chinese
第七届董事会第四次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of the resolutions passed at the fourth meeting of the seventh board of directors of Jinling Pharmaceutical Co., Ltd. It includes details about the meeting date, method, attendance, and voting results. It does not contain financial statements or detailed financial analysis but rather focuses on board meeting decisions and procedural compliance. This fits the category of Board/Management Information (MANG), which covers announcements of changes or decisions by the company's board of directors.
2017-12-05 Chinese
关于收购湖州市社会福利中心发展有限公司股权项目进展情况的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by Jinling Pharmaceutical Co., Ltd. regarding the progress of an equity acquisition project involving Huzhou Social Welfare Center Development Co., Ltd. It details the signing of a supplemental agreement to a previous intention letter, the terms of the equity transfer, and the completion of shareholder change registration with the local industrial and commercial bureau. The document includes specific transaction details, parties involved, and changes in shareholding percentages. It is a formal announcement about a capital acquisition transaction and its progress, not a full financial report, earnings release, or regulatory certification. Therefore, it fits best under the category of Capital/Financing Update (CAP). The document length is short and focused on the transaction progress, not a full report or audit.
2017-11-28 Chinese
第七届董事会第三次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of the resolutions passed at the third meeting of the seventh board of directors of Jinling Pharmaceutical Co., Ltd. It includes details about the meeting date, attendance, and the approval of the company's 2017 third quarter report and internal organizational adjustments. The document does not contain the full third quarter report itself but references where the full report can be found (on the designated website and newspapers). The document also includes voting results and mentions compliance with legal and regulatory requirements. Given the content, this is a Board/Management Information announcement about board meeting resolutions and internal management changes, not the actual quarterly report or financial statements. Therefore, the appropriate classification is MANG (Board/Management Information). The document length is short (1228 characters), consistent with an announcement rather than a full report.
2017-10-30 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.